Amatuximab

N/A

Report date: 2022/11/25 16:34:12

Base Information

Drug NameAmatuximab
Drug Alias NameMORAb-009MORAB-009-006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-Mesothelin
TargetsMesothelin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteMorphotek IncEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG